On Wednesday, Johnson & Johnson (NYSE:JNJ) reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, beating the consensus of $2.01.
The pharmaceutical giant reported sales of $22.52 billion, up 5.3% year over year and beating the consensus of $22.44 billion.
Operational growth was 6.7%, and adjusted operational growth was 5.7%.
Innovative Medicine sales increased to $14.33 billion, up 4.4% (+6.1% adjusted operational).
Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), driven by continued strong share gains and market growth. Overall cancer sales increased to $5.49 billion.
Also Read: FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
Growth was partially offset by Stelara (ustekinumab). Stelara sales fell 14.7% to $2.35 billion. Darzalex sales rose 20.9% to $3.08 billion. The company's cancer cell therapy, Carvykti, generated sales of $334 million.
MedTech sales increased 6.7% to 8.19 billion, driven by global procedure growth, new product performance, and the Shockwave deal. Growth was partially offset by endocutter products in Advanced Surgery.
Guidance: Johnson & Johnson expects 2025 sales of $90.9 billion—$91.7 billion, compared to the consensus of $90.99 billion. The Medtech giant expects 2025 adjusted EPS of $10.75–$10.95 versus a consensus of $10.59.
The company expects to accelerate the launch of newly launched products in the MedTech segment, with the full benefit of the Shockwave acquisition through May. JNJ sees normalized procedure volume and seasonality.
Intra-Cellular Therapies is a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders.
Price Action: At last check on Wednesday, JNJ stock was down 1.69% to $145.65 during the premarket session.
Read Next:
Image By Sundry Photography Via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
